{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:04:03Z","timestamp":1740107043812,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Grant-in-Aid for Scientific Research","award":["19K09041"],"award-info":[{"award-number":["19K09041"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00432-019-02947-7","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T08:02:32Z","timestamp":1559203352000},"page":"2097-2104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Does sunitinib have a patient-specific dose without diminishing its antitumor effect on advanced pancreatic neuroendocrine neoplasms?"],"prefix":"10.1007","volume":"145","author":[{"given":"Satoshi","family":"Matsui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5301-3847","authenticated-orcid":false,"given":"Atsushi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Mitsunori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,30]]},"reference":[{"key":"2947_CR1","first-page":"471","volume":"2","author":"TJ Abrams","year":"2003","unstructured":"Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Therap 2:471\u2013478","journal-title":"Mol Cancer Therap"},{"key":"2947_CR2","doi-asserted-by":"publisher","first-page":"6413","DOI":"10.21873\/anticanres.13002","volume":"38","author":"M Boegemann","year":"2018","unstructured":"Boegemann M, Hubbe M, Thomaidou D, Blackburn S, Bent-Ennakhil N, Wood R, Bargo D (2018) Sunitinib treatment modification in first-line metastatic renal cell carcinoma: analysis of the STAR-TOR registry. Anticancer Res 38:6413\u20136422. \n                              https:\/\/doi.org\/10.21873\/anticanres.13002","journal-title":"Anticancer Res"},{"key":"2947_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","volume":"8","author":"O Casanovas","year":"2005","unstructured":"Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299\u2013309. \n                              https:\/\/doi.org\/10.1016\/j.ccr.2005.09.005","journal-title":"Cancer Cell"},{"key":"2947_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/annonc\/mdw561","volume":"28","author":"S Faivre","year":"2017","unstructured":"Faivre S et al (2017) Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol 28:339\u2013343. \n                              https:\/\/doi.org\/10.1093\/annonc\/mdw561","journal-title":"Ann Oncol"},{"key":"2947_CR5","first-page":"1469","volume":"9","author":"ML Fjallskog","year":"2003","unstructured":"Fjallskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET (2003) Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9:1469\u20131473","journal-title":"Clin Cancer Res"},{"key":"2947_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","volume":"66","author":"BE Houk","year":"2010","unstructured":"Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis. Cancer Chemotherap Pharmacol 66:357\u2013371. \n                              https:\/\/doi.org\/10.1007\/s00280-009-1170-y","journal-title":"Cancer Chemotherap Pharmacol"},{"key":"2947_CR7","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s10637-012-9910-y","volume":"31","author":"T Ito","year":"2013","unstructured":"Ito T et al (2013) Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Investig New Drugs 31:1265\u20131274. \n                              https:\/\/doi.org\/10.1007\/s10637-012-9910-y","journal-title":"Investig New Drugs"},{"key":"2947_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00535-014-0934-2","volume":"50","author":"T Ito","year":"2015","unstructured":"Ito T et al (2015) Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol 50:58\u201364. \n                              https:\/\/doi.org\/10.1007\/s00535-014-0934-2","journal-title":"J Gastroenterol"},{"key":"2947_CR9","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res 9:327\u2013337","journal-title":"Clin Cancer Res"},{"key":"2947_CR10","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00432-018-2636-2","volume":"144","author":"Y Mizuno","year":"2018","unstructured":"Mizuno Y et al (2018) Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol 144:1155\u20131163. \n                              https:\/\/doi.org\/10.1007\/s00432-018-2636-2","journal-title":"J Cancer Res Clin Oncol"},{"key":"2947_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med 356:115\u2013124. \n                              https:\/\/doi.org\/10.1056\/NEJMoa065044","journal-title":"New Engl J Med"},{"key":"2947_CR12","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New Engl J Med 369:722\u2013731. \n                              https:\/\/doi.org\/10.1056\/NEJMoa1303989","journal-title":"New Engl J Med"},{"key":"2947_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1023\/B:CLIN.0000006873.65590.68","volume":"20","author":"LJ Murray","year":"2003","unstructured":"Murray LJ et al (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757\u2013766","journal-title":"Clin Exp Metastasis"},{"key":"2947_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1196\/annals.1294.025","volume":"1014","author":"UF Pape","year":"2004","unstructured":"Pape UF, Bohmig M, Berndt U, Tiling N, Wiedenmann B, Plockinger U (2004) Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center. Ann N Y Acad Sci 1014:222\u2013233","journal-title":"Ann N Y Acad Sci"},{"key":"2947_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M et al (2016) ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103:172\u2013185. \n                              https:\/\/doi.org\/10.1159\/000443167","journal-title":"Neuroendocrinology"},{"key":"2947_CR16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New Engl J Med 364:501\u2013513. \n                              https:\/\/doi.org\/10.1056\/NEJMoa1003825","journal-title":"New Engl J Med"},{"key":"2947_CR17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12325-011-0099-9","volume":"29","author":"S Vazquez","year":"2012","unstructured":"Vazquez S, Leon L, Fernandez O, Lazaro M, Grande E, Aparicio L (2012) Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma. Adv Therap 29:202\u2013217. \n                              https:\/\/doi.org\/10.1007\/s12325-011-0099-9","journal-title":"Adv Therap"},{"key":"2947_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00280-017-3367-9","volume":"80","author":"Y Wang","year":"2017","unstructured":"Wang Y et al (2017) Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors: a multicenter retrospective study in China. Cancer Chemother Pharmacol 80:507\u2013516. \n                              https:\/\/doi.org\/10.1007\/s00280-017-3367-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"2947_CR19","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC et al (2008) One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063\u20133072. \n                              https:\/\/doi.org\/10.1200\/jco.2007.15.4377","journal-title":"J Clin Oncol"},{"key":"2947_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00280-016-3215-3","volume":"79","author":"C Yoo","year":"2017","unstructured":"Yoo C et al (2017) Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. Cancer Chemother Pharmacol 79:139\u2013146. \n                              https:\/\/doi.org\/10.1007\/s00280-016-3215-3","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-02947-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-019-02947-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-02947-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T19:10:00Z","timestamp":1590693000000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-019-02947-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,30]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["2947"],"URL":"https:\/\/doi.org\/10.1007\/s00432-019-02947-7","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2019,5,30]]},"assertion":[{"value":"15 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}